News Takeda's narcolepsy programme gets back on track Takeda will move quickly ahead with regulatory filings for oveporexton as a treatment for narcolepsy after a pair of phase 3 wins.
News AZ prepares to file blood pressure drug after trial win Two years after buying CinCor for $1.3 billion, AstraZeneca has reported that the main asset in the deal has cleared a phase 3 trial.
News Case builds for Biogen, Stoke's Dravet syndrome drug Hopes have risen for a new treatment for severe childhood epilepsy Dravet syndrome, on the back of new data for Biogen and Stoke's zorevunersen.
Patients New Evidation CEO to double down on patient data empowerment pharmaphorum spoke with Leslie Olay Wilberforce, Evidation's new CEO, about the company's unique approach to real-world data and her future plans.
News Taiho's late-stage Duchenne candidate fails trial Taiho has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy (DMD) missed the mark in a phase 3 trial.
News Boehringer raises hope of oral drug for diabetic eye disease Boehringer has started a phase 2 trial of an oral therapy that could help people with diabetic macular oedema avoid regular injections into the eye.
News Takeda's narcolepsy programme gets back on track Takeda will move quickly ahead with regulatory filings for oveporexton as a treatment for narcolepsy after a pair of phase 3 wins.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
